February 16, 2017
On February 15, 2017, Johnson & Johnson received a binding offer from Integra LifeSciences Holdings Corporation to acquire its Codman Neurosurgery business for $1.045 billion in cash. Codman Neurosurgery offers a portfolio of devices focused on advanced hydrocephalus, neuro‑critical care and operative neurosurgery. If the binding offer is accepted, upon closing, Integra will be a leading global provider of neurosurgical products. Cravath is representing Johnson & Johnson in connection with the transaction.
The Cravath team is led by partner Robert I. Townsend III and includes associates Cameron S. Stanton, Vince A. Ferrito and Megan E. Fitzgerald on M&A matters; partner Craig F. Arcella on financing matters; partner J. Leonard Teti II and associates Sara L. Lykken and Lingfeng Li on tax matters; partner Jonathan J. Katz and associates Matthew J. Bobby and Peretz Riesenberg on executive compensation and benefits matters; partner Matthew Morreale on environmental matters; and associate Jason M. Sandler on intellectual property matters.
Deals & Cases
March 12, 2025
Cravath represented the underwriters in connection with the $5 billion registered notes offering of Johnson & Johnson, the world’s largest, most diversified healthcare products company. Cravath also represented the underwriters in connection with Johnson & Johnson’s concurrent €4 billion notes offering. Proceeds of both offerings will be used to finance the acquisition of Intra‑Cellular Therapies, Inc. by Johnson & Johnson. The transactions closed on February 20, 2025, and February 26, 2025, respectively.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.